# Stingray Therapeutics

Source: https://onco.cc/companies/stingray-therapeutics/  
OnCo record `stingray-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Stingray Therapeutics is a Houston company developing vizenpistat, a tablet designed to switch back on an early-warning part of the immune system that many tumours turn off. It is being tested with two immunotherapy antibodies in bowel cancer that is microsatellite stable.

## Summary

Stingray Therapeutics develops vizenpistat (SR-8541A), an oral inhibitor of ENPP1, the enzyme that breaks down 2'3'-cGAMP before it can activate STING; the company describes blocking ENPP1 as a way to restore cGAS-STING innate immune signalling. Its website lists a phase 1 single-agent dose-escalation study in advanced solid tumours (NCT06063681) and a phase 1b/2 study with botensilimab and balstilimab in metastatic microsatellite stable colorectal cancer (NCT06589440), funded by a CPRIT grant and an NCI SBIR award. In fiscal year 2026 NCI awarded it USD 1,460,952 under SBIR award 5R44CA278144-04 for that colorectal programme.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Stingray Therapeutics, Inc.
- HQ: Houston, TX
- Type: biotech
- Website: https://www.stingraytx.com/

## Notes

- Read on stingraytx.com, NIH RePORTER and ClinicalTrials.gov on 4 November 2026. The company's ranking and safety claims are its own. No ENPP1 target record exists in the corpus.

## Sources

- Official website: https://www.stingraytx.com/
- NIH RePORTER: SBIR award 5R44CA278144-04: https://reporter.nih.gov/project-details/11393170
- ClinicalTrials.gov: phase 1 trial of SR-8541A (NCT06063681): https://clinicaltrials.gov/study/NCT06063681

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Vizenpistat](https://onco.cc/drugs/vizenpistat/)
- trials: [Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Can](https://onco.cc/trials/nct06589440/)

---
JSON: https://onco.cc/api/v1/entities/stingray-therapeutics.json